In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
As of close of business last night, Cytokinetics Inc’s stock clocked out at $42.92, up 0.19% from its previous closing price of $42.84. In other words, the price has increased by $0.19 from its previous closing price. On the day, 1.73 million shares were traded. CYTK stock price reached its highest trading level at $43.42 during the session, while it also had its lowest trading level at $42.0.
Ratios:
To gain a deeper understanding of CYTK’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.17 and its Current Ratio is at 6.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on April 24, 2025, initiated with a Overweight rating and assigned the stock a target price of $55.
On February 07, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $86.
On January 22, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $80.Stifel initiated its Buy rating on January 22, 2025, with a $80 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 29 ’25 when Blum Robert I sold 5,000 shares for $40.96 per share. The transaction valued at 204,800 led to the insider holds 417,629 shares of the business.
Malik Fady Ibraham sold 2,000 shares of CYTK for $76,220 on Apr 22 ’25. The EVP Research & Development now owns 140,255 shares after completing the transaction at $38.11 per share. On Apr 21 ’25, another insider, WIERENGA WENDALL, who serves as the Director of the company, sold 20,000 shares for $38.46 each. As a result, the insider received 769,200 and left with 24,848 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 5115548672 and an Enterprise Value of 4929353728. For the stock, the TTM Price-to-Sale (P/S) ratio is 276.96. Its current Enterprise Value per Revenue stands at 266.827 whereas that against EBITDA is -9.359.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.81, which has changed by -0.3424238 over the last 52 weeks, in comparison to a change of 0.092895746 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $68.44, while it has fallen to a 52-week low of $32.74. The 50-Day Moving Average of the stock is 1.46%, while the 200-Day Moving Average is calculated to be -13.75%.
Shares Statistics:
It appears that CYTK traded 1.98M shares on average per day over the past three months and 1400420 shares per day over the past ten days. A total of 118.21M shares are outstanding, with a floating share count of 116.04M. Insiders hold about 2.64% of the company’s shares, while institutions hold 109.58% stake in the company. Shares short for CYTK as of 1744675200 were 13947306 with a Short Ratio of 7.04, compared to 1741910400 on 14220519. Therefore, it implies a Short% of Shares Outstanding of 13947306 and a Short% of Float of 15.27.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Its stock is currently analyzed by 15.0 different market analysts. The consensus estimate for the next quarter is -$1.4, with high estimates of -$1.23 and low estimates of -$1.64.
Analysts are recommending an EPS of between -$4.9 and -$6.65 for the fiscal current year, implying an average EPS of -$5.64. EPS for the following year is -$4.95, with 15.0 analysts recommending between -$3.75 and -$6.51.
Revenue Estimates
A total of 19 analysts have provided revenue estimates for CYTK’s current fiscal year. The highest revenue estimate was $90.3M, while the lowest revenue estimate was $3.47M, resulting in an average revenue estimate of $35.64M. In the same quarter a year ago, actual revenue was $18.47MBased on 18 analysts’ estimates, the company’s revenue will be $210.82M in the next fiscal year. The high estimate is $396.1M and the low estimate is $103.3M.
